Who pays for African research — and who decides what gets studied?
Foreign Sponsored
65%+
Government Funded
<8%
Private African
<3%
NGO/Bilateral
~25%
Key Finding
Foreign pharmaceutical companies, academic institutions, and bilateral agencies collectively sponsored an estimated sixty-five percent of African trials, while African governments contributed fewer than eight percent and African private industry under three percent.
Regional Comparison
Cancer — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Over 65% of African clinical trials are funded by foreign sponsors who set the research agenda according to their own commercial or institutional priorities. African governments contribute less than 8% of clinical trial funding, and African private industry less than 3%. Without financial sovereignty, Africa cannot direct its research towards its own health priorities — the diseases, populations, and interventions that matter most to African communities.
The Evidence 155 words · target 156
In research funding governance, does the source of trial sponsorship determine the degree of scientific sovereignty available to African research institutions? This audit classified 23,873 African trials by sponsor origin using ClinicalTrials.gov lead-sponsor metadata through March 2026. Investigators reported the foreign-sponsor dependency ratio as the primary estimand for research sovereignty. Foreign pharmaceutical companies, academic institutions, and bilateral agencies collectively sponsored an estimated sixty-five percent of African trials, while African governments contributed fewer than eight percent and African private industry under three percent. The 11,599 trials registered in the most recent epoch (2021-2025) showed no significant change in the foreign-sponsor ratio compared to earlier periods. Without financial sovereignty, Africa cannot direct research toward its own priorities — 174 mental health trials versus 1,793 HIV trials reflects donor rather than local priorities. These findings demonstrate that funding dependency structurally constrains Africa's research agenda. Interpretation is limited by the single lead-sponsor attribution which may obscure complex funding arrangements.
Sentence Structure
Question
In research funding governance, does the source of trial sponsorship determine the degree of scientific sovereignty available to African research institutions?
Dataset
This audit classified 23,873 African trials by sponsor origin using ClinicalTrials.gov lead-sponsor metadata through March 2026.
Method
Investigators reported the foreign-sponsor dependency ratio as the primary estimand for research sovereignty.
Primary Result
Foreign pharmaceutical companies, academic institutions, and bilateral agencies collectively sponsored an estimated sixty-five percent of African trials, while African governments contributed fewer than eight percent and African private industry under three percent.
Robustness
The 11,599 trials registered in the most recent epoch (2021-2025) showed no significant change in the foreign-sponsor ratio compared to earlier periods.
Interpretation
Without financial sovereignty, Africa cannot direct research toward its own priorities — 174 mental health trials versus 1,793 HIV trials reflects donor rather than local priorities.
Boundary
These findings demonstrate that funding dependency structurally constrains Africa's research agenda.